CluenexCertara, Inc. CERT
Certara, Inc. scores weak on business quality (3.9 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Certara, Inc. does
Certara sells biosimulation software and regulatory consulting to biopharmaceutical companies, helping them simulate clinical trials digitally. The business is navigating AI-led R&D disruption as the industry accelerates virtual drug discovery.
- What it does best
Certara dominates biosimulation software with a gross margin of 62.0%, anchoring its lock-in through regulatory workflows. DOCS achieves an 88.0% gross margin, but Certara holds a specialized niche in digital trial modeling that rivals cannot easily duplicate.
- The main risk
Net losses of $68.0 million and negative interest coverage signal structural unprofitability, leaving little room for operational missteps as research spending shifts toward competing AI-driven discovery platforms.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin stands at -0.3% and net margin at -16.7%, driven by heavy expenses relative to revenue. The business fails to scale profitably despite a strong free cash flow margin of 49.0%.
The moat relies on regulatory and developer lock-in within biopharma R&D, placing it in the middle of the pack with a revenue growth sector percentile of 54.
Revenue growth printed at 8.8%, showing deceleration from prior years when history annual summary shows revenue at $419.0 million down from previous highs, signaling moderating top-line momentum.
Total debt sits at $293.0 million against $189.0 million in cash, leaving $104.0 million in net debt. Free cash flow reached $55.0 million, supporting debt service while the balance sheet softens.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on CERT
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Certara, Inc. scores weak on the Cluenex quality check (3.9 of 10), measured against its own industry. Profitability is weak, moat fair, growth steady and financial health weak.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Nov 2, 2026, after the close.
See CERT today
- Today's verdict on CERT, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Certara, Inc. (CERT)”, https://cluenex.com/stocks/cert/, data as of Oct 10, 2026.